RESEARCH TRIANGLE PARK, N.C. (March 28, 2012) – SCYNEXIS, Inc. announced today
that it has signed an agreement with Abide Therapeutics to collaborate in the search for novel
anti-viral and anti-parasitic therapeutic compounds for human and animal health applications.
Under the agreement, SCYNEXIS will screen, through its diverse biological screening platforms,
Abide’s proprietary serine hydrolase inhibitor library with the objective of identifying compounds
for advancement to the preclinical stage.

“Abide Therapeutics has a unique technology platform that exploits a chemoproteomics
approach to selectively target serine hydrolases and rapidly identify target lead pairs. We are
very excited to explore our discovery platform in the biological systems that SCYNEXIS brings
to bear. Importantly, this collaboration has the potential to bring new therapies for a range of
infectious diseases,” said Alan Ezekowitz MBChB, D.Phil, president and chief executive officer
of Abide Therapeutics.

“SCYNEXIS is gratified that Abide Therapeutics, with its innovative technology, is joining us in
the search for innovative anti-parasitic technologies to address human and animal diseases,”
said Yves Ribeill, Ph.D., president and chief executive officer of SCYNEXIS. “We look forward
to partnering our technologies in this exciting search.”

About SCYNEXIS, Inc.
SCYNEXIS delivers integrated, efficient and innovative drug discovery and development
solutions to our global health and pharmaceutical partners. Our record of success is
exemplified by the eleven pre-clinical and clinical candidates delivered to our clients and
partners in the last five years. SCYNEXIS’ contract research and development services include
Integrated Pharmaceutical Solutions, Discovery Research and Integrated Parasitology.
Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. For more
information please visit www.scynexis.com.

About Abide Therapeutics
Our mission is to develop innovative medicines for the benefit of human health that target serine
hydrolases, one of the largest enzyme classes in nature with validated, but mostly untapped
therapeutic potential.

For further information, please contact:

SCYNEXIS, Inc.
Terry Marquardt
Executive Director, Market Development & Communications
terry.marquardt@scynexis.com
Tel: +1-919-544-8603

SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144

Abide Therapeutics
Deborah Walker
Administrator
Debbie@abidetx.com
Tel.+1- 760-315-6259

[Geneva, Switzerland – 12 March 2012] – The Drugs for Neglected Diseases initiative (DNDi) has
commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and
tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African
trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability,
pharmacokinetics and pharmacodynamics of SCYX-7158 in healthy volunteers. The study is a combined
trial including three sequential parts: first, administration of single oral ascending doses; second,
concomitant food intake with single oral dose administration, in order to assess the bioavailability of
SCYX-7158 (food effect); and third, administration of multiple oral ascending dose. The study is taking
place in a Phase I unit in Paris, at SGS Aster, and will recruit up to 120 volunteers.

Approval for the study was obtained from a French Ethics Committee (Comité de Protection des
Personnes) and the French Regulatory Authority AFSSAPS (Agence Française de Sécurité Sanitaire des
Produits de Santé).

‘This is an important milestone in our efforts to build and maintain a strong pipeline for new oral
treatments against sleeping sickness. DNDi and its partners are committed to harnessing all of the
efforts and expertise necessary to support the WHO goal of eliminating this disease by the year 2020.
New oral treatments that can be administered at the field level would be a vital part of this’, comments
Dr Bernard Pécoul, Executive Director, DNDi.

Oxaborole SCYX-7158 is DNDi’s first clinical candidate issued from the DNDi Lead Optimization
Consortium to enter Phase I trials. The development of the compound was the result of a unique
collaboration between DNDi and Anacor Pharmaceuticals (USA), SCYNEXIS (USA), within a consortium
including also Pace University (USA) and the Swiss Tropical and Public Health Institute (Switzerland).
Together they worked on the Oxaboroles series and amongst the molecules studied, SCYX-7158 was
selected for its very promising pre-clinical results.

If Oxaborole SCYX-7158 progresses successfully through Phase I clinical trials, DNDi plans to advance the
treatment into a multi-center Phase II trial in sub-Saharan African countries where the disease occurs.

###

About sleeping sickness
Sleeping sickness, which threatens millions in 36 countries in sub-Saharan Africa, is fatal if left
untreated. The disease is caused by parasites transmitted by the bite of a tsetse fly and is often
asymptomatic for years (stage 1) until the infection reaches stage 2, where it crosses into the central
nervous system and brain. Currently available treatments are limited to drugs developed decades ago
that are either highly toxic, difficult to administer in resource-limited settings, or are only effective in
one stage of the disease. In addition, prior to being treated, the stage of the disease must be
determined using a diagnostic spinal tap to extract cerebrospinal fluid from the patient.

About the partnership
A collaboration led by the Drugs for Neglected Disease initiative (DNDi) combined Anacor
Pharmaceuticals’ novel boron chemistry with the chemistry and parasitology expertise at SCYNEXIS. A
scientific consortium led by DNDi and including SCYNEXIS, Pace University, Swiss Tropical and Public
Health Institute, and Anacor worked on the optimization of a series of benzoxaboroles, which led to the
discovery of SCYX-7158. Advinus Therapeutics conducted toxicology testing on the compound. The
project has mostly been supported by the Bill & Melinda Gates Foundation and the Ministry of Foreign
and European Affairs (MAEE), France. Additional funding is provided by the Department for
International Development (DFID), UK, Dutch Ministry of Foreign Affairs (DGIS), The Netherlands,
Spanish Agency of International Cooperation for Development (AECID), Spain, Federal Ministry of
Education and Research (BMBF), Germany, Swiss Agency for Development and Cooperation (SDC),
Switzerland, and Doctors Without Borders/Médecins Sans Frontières (MSF).

For more information on the partnership:
Sleeping Sickness Background Document_June 2011.pdf

About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development
organization working to deliver new treatments for neglected diseases, in particular sleeping sickness
(human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, malaria,
and paediatric HIV. DNDi was established in 2003 by Médecins Sans Frontières/Doctors Without Borders
(MSF), the Oswaldo Cruz Foundation (FIOCRUZ) of Brazil, the Indian Council of Medical Research (ICMR),
the Kenya Medical Research Institute (KEMRI), the Ministry of Health of Malaysia, and the Pasteur
Institute of France. The Special Programme for Tropical Disease Research (WHO/TDR) serves as
permanent observer.

Since its inception in 2003, DNDi has delivered six new treatments for neglected patients: two fixeddose
antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage
sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral
leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric
dosage form of benznidazole for Chagas disease.

DNDi has helped establish three clinical research platforms: Leishmaniasis East Africa Platform (LEAP) in
Kenya, Ethiopia, Sudan, and Uganda; the HAT Platform based in the Democratic Republic of Congo (DRC)
for sleeping sickness; and the Chagas Clinical Research Platform in Latin America. Strong regional
networks such as these help strengthen research and treatment-implementation capacity in neglected
disease-endemic countries.
www.DNDi.org

Media contact
Violaine Dällenbach
Press and Communications Manager
office: +41 22 906 92 47
mobile: +41 79 424 14 74
email: vdallenbach@DNDi.org

RESEARCH TRIANGLE PARK, N.C. (Feb. 16, 2012) – Morria Biopharmaceuticals Plc has selected SCYNEXIS, Inc. as their chemical development and production partner for the first-in-class non-steroidal anti-inflammatory drug MRX-4 for treatment of allergic rhinitis. MRX-4 is a first in class inhibitor of sPLA2 that has been demonstrating excellent safety and promising potency in pre-clinical and clinical studies.

Morria’s technology platform of multi-functional anti-inflammatory drugs (MFAIDs) targeting the sPLA2 family of enzymes presented unique demands in terms of synthesis, isolation and analysis. SCYNEXIS’ chemical and analytical development teams worked closely with Morria’s in-house team and successfully addressed these issues, enabling production and analysis in a cost-effective and efficient manner. Morria’s original synthesis and analysis procedures were dramatically reshaped and improved, increasing volume efficiency, product quality and yield. Efficient and readily transferable analytical methods were also developed.

“We have been consistently impressed with SCYNEXIS’ team and facilities,” said Dr. Joseph Bondi, vice president of pre-clinical development at Morria Biopharmaceuticals. “The level of expertise, dedication, regulatory compliance and creativity shown has been truly outstanding.”

“We are pleased to have had the opportunity to contribute to this groundbreaking approach to treatment of inflammatory conditions,” said Dr. Yves Ribeill, chief executive officer of SCYNEXIS. “Over the years, our teams have demonstrated the ability to solve diverse development problems in order to move important new treatments to patients. This project is another excellent example.”

About SCYNEXIS, Inc.
SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by numerous pre-clinical and clinical candidates delivered to our clients and partners in all major therapeutic indications. SCYNEXIS’ contract research and development services include Integrated Pharmaceutical Solutions, Discovery Research and Integrated Parasitology. Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. Please visit www.scynexis.com.

About Morria Biopharmaceuticals Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs termed multi-functional anti-inflammatory drugs (MFAIDs). Morria is determined to become a pivotal player in the anti-inflammatory drug market by developing and commercializing novel drugs for respiratory, dermatology, pulmonary, gastro-intestinal and ophthalmological inflammatory diseases. Morria’s lead drugs are MRX6 in dermatitis and MRX4 in allergic rhinitis and have each completed first-in-patient studies showing excellent safety and promising potency. Further clinical studies are scheduled for 2012.
For more information, please visit www.morria.com.

For further information, please contact:

SCYNEXIS, Inc.
Terry Marquardt
Executive Director, Market Development & Communications
terry.marquardt@scynexis.com
Tel: +1-919-544-8603

SCYNEXIS Media Contact:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144

Morria Biopharmaceuticals Plc
Yuval Cohen
President
Tel: +44 (0)207 152 6341
Email: info@morria.com

GENEVA, SWITZERLAND (December 19,2011) — In a bid to catalyse malaria and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a Malaria Box of 400 carefully selected commercially available compounds with antimalarial activity and will provide it to researchers at no cost.

All 400 compounds in the Malaria Box have confirmed activity against the blood-stage of P. falciparum – the most deadly of the malaria parasites – and were selected by experienced medicinal chemists from an extensive screening of around four million compounds from the chemical libraries of St. Jude Children’s Research Hospital, Novartis and GlaxoSmithKline. The Malaria Box includes 200 drug-like compounds as starting points for oral drug discovery as well as 200 probe-like compounds representing the broadest cross-section of chemical diversity for use as biological tools.

“The discovery of novel molecules to feed the pipeline of antimalarial drugs remains a constant challenge,” said Tim Wells, CSO of Medicines for Malaria Venture, “and all the more pressing in light of emerging resistance to current therapies. One of the rate-limiting factors for drug discovery is access to the actual active compounds with which to conduct research. With the Malaria Box concept, together with our partner SCYNEXIS, we hope to overcome this hurdle by carefully selecting and making available the most promising molecules to propel malaria drug discovery to the next level.”

The scope of the Malaria Box goes beyond the malaria field as the compounds could also be used in research for drugs for other parasitic or neglected diseases. Making the compounds available to the entire neglected-disease community could lead to a better understanding of the similarities and differences between these diseases.

“SCYNEXIS is pleased to participate with MMV in the Malaria Box project as part of our on-going commitment to address the tremendous challenges presented by neglected diseases,” said Yves Ribeill, President & CEO of SCYNEXIS, Inc. “SCYNEXIS stands ready to direct its proprietary technologies including its Integrated Parasitology Screening Platform and its HEOS® Collaborative Discovery Information Software Platform along with its highly experienced drug discovery teams to find innovative cures for these diseases.”

The Malaria Box can be requested free-of-charge from MMV’s website: www.mmv.org/malariabox. All that is asked in return is that any data gleaned from research on the Box is published, shared and placed into the public domain to continue the virtuous cycle of research.

About MMV
MMV is recognized as the leading product development partnership (PDP) in the field of antimalarial drug research and development. It was established as a foundation in 1999, and registered in Switzerland.

MMV’s mission is to reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.

MMV’s vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.

MMV’s strength comes from its product development partnership (PDP) model reflected in its network of more than 170 pharmaceutical, academic and endemic-country partners in 45 countries. MMV also works in close partnership with a number of WHO programmes that include TDR, the Global Malaria Programme (GMP) and Roll Back Malaria (RBM).

The key to MMV’s success lies in the focus of its mission, and the diversity of its team of almost 50 personnel from more than 20 countries, handpicked for their expertise and commitment to global health. Governed by the values of respect, integrity, trust and excellence, MMV is recognized for its industry-style portfolio management and wise administration of funds. It manages funds received and committed from long-term donors such as government agencies, private foundations, international organizations, and corporate foundations. In addition, it receives in-kind donations in the form of staff, facilities, and technology from its industry partners, estimated to be equal in dollar value to the funds from donors.

MMV is currently managing the largest portfolio of antimalarial R&D projects ever assembled. Of over 50 promising projects, one MMV-supported artemisinin combination therapy (ACT), Pyramax®, is undergoing regulatory review by the European Medicines Agency (EMA). In October 2011 dihydroartemisinin-piperaquine (Eurartesim®), an ACT developed in partnership with sigma-tau, was granted regulatory approval by the EMA and, in November 2010, Guilin’s artesunate injection for the treatment of severe malaria was approved by the WHO’s Prequalification programme with assistance from MMV. In addition, Coartem® Dispersible, a child-friendly version of the ACT Coartem, was developed by Novartis in partnership with MMV and launched in 2009. Since then, more than 92 million courses of treatment have been supplied to 35 malaria-endemic countries.

About SCYNEXIS
SCYNEXIS delivers efficient and innovative drug discovery and development solutions to our global health partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last five years including a clinical candidate (SCYX-7158) for African sleeping sickness delivered to the Drugs for Neglected Diseases initiative (DNDi). SCYNEXIS’ teams are available to take projects forward for industrial, academic, PDP and other partners to help address the challenges of global health. We are supported by an extensive network of global technical experts.

SCYNEXIS has developed a robust screening platform for the assessment of compounds against parasite species relevant to neglected tropical diseases. The platform is designed to identify compounds with potential activity in the areas of human health and public health.

Discovery teams consisting of medicinal chemistry, parasitology, computational chemistry, in vitro pharmacology, ADMET-PK/bioanalytical chemistry are available through SCYNEXIS Integrated Parasitology and tailored to our customers’ needs. In addition, SCYNEXIS applies its powerful proprietary technologies such as HEOS® SaaS Discovery Information Software Platform for comprehensive drug discovery information management and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform to rapidly and effectively progress drug discovery projects.

For more information about MMV and the Malaria Box please contact:

Jaya Banerji
Director, Advocacy & Communications, MMV
Tel: +41 (0) 22 799 4071
Mobile: +41 (0) 79 707 7181
Email: banerjij@mmv.org

For more information about SCYNEXIS please contact:

Terry Marquardt
Executive Director
Market Development & Communications, SCYNEXIS
terry.marquardt@scynexis.com
Tel: +1-919-544-8603

MMV Disclaimer

This document contains certain forward-looking statements that may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions, or by discussion of, among other things, vision, strategy, goals, plans, or intentions. It contains hypothetical future product target profiles, development timelines and approval/launch dates, positioning statements, claims and actions for which the relevant data may still have to be established. Stated or implied strategies and action items may be implemented only upon receipt of approvals including, but not limited to, local institutional review board approvals, local regulatory approvals, and following local laws and regulations. Thus, actual results, performances or events may differ from those expressed or implied by such statements.

We ask you not rely unduly on these statements. Such forward-looking statements reflect the current views of Medicines for Malaria Venture (MMV) and its partner(s) regarding future events, and involve known and unknown risks and uncertainties.

MMV accepts no liability for the information presented here, nor for the consequences of any actions taken on the basis of this information. Furthermore, MMV accepts no liability for the decisions made by its pharmaceutical partner(s), the impact of any of their decisions, their earnings and their financial status.

RESEARCH TRIANGLE PARK, N.C. – November 7, 2011 — Drug discovery company SCYNEXIS, Inc. today presented data demonstrating that SCY-635—a novel, oral cyclophilin inhibitor being studied for the treatment of hepatitis C virus (HCV) infection—reactivates the body’s natural defense mechanism, making it capable of inhibiting replication of the virus. The data positions SCY-635 as a potential replacement for recombinant interferon—a component of the standard of care for hepatitis C treatment that is associated with significant side effects. The data were presented in a poster session at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. SCY-635 is currently undergoing Phase 2 studies.

“The results of this study introduce a completely novel mechanism to treat HCV and suggest that our oral cyclophilin inhibitor, SCY-635, could potentially replace recombinant interferon—a primary goal in the development of new treatment protocols for this disease,” said Yves Ribeill, Ph.D., President and Chief Executive Officer of SCYNEXIS. “HCV is a complex disease where the virus cloaks and hides itself from the body’s immune system. SCY-635 uncloaks the virus – making it visible to the immune system. In studies conducted to date, SCY-635 has been well-tolerated and demonstrated single-agent, clinically meaningful activity. It has also demonstrated an excellent in vitro drug – drug interaction profile with other approved products and leading products in clinical development, suggesting that SCY-635 could play an important role in the quest for a new standard of care in HCV.”

“This is different than other therapeutic approaches to eradicating HCV because SCY-635 acts primarily at the level of the host innate immune response pathway,” said Sam Hopkins, Ph.D., Chief Scientific Officer of SCYNEXIS. “Acting predominantly at the level of a host target, cyclophilin A, lessens the likelihood of developing resistance which is typically associated with direct acting antiviral agents.”

In the poster presentation entitled, “The Non-Immunosuppressive Cyclophilin Inhibitor SCY-635 Exerts Clinical Anti-HCV Activity by Up Regulating the Expression of Endogenous Interferons,” SCYNEXIS demonstrated that treatment with SCY-635 monotherapy resulted in dose and concentration dependent increases in the plasma protein concentrations of multiple endogenous interferons including interferon alpha and interferon lambda-1 in patients chronically infected with genotype 1a hepatitis C virus. The upregulated expression of multiple interferons was associated with increased expression of interferon stimulated genes . The data also show a correlation of SCY-635 plasma levels and the expression of type 1 and type 3 interferons; the presence of these interferons demonstrate that the body is now able to respond to the virus.

SCYNEXIS also presented two additional studies of SCY-635 at AASLD. In one study, SCYNEXIS showed that consistent with the clinical observations, SCY-635 results in an increased expression of multiple type 1 and 3 interferons in vitro and that SCY-635 is equally as effective as IFNα-2b in clearing HCV and preventing viral rebound in vitro. The final study examined potential drug interactions between SCY-635 and telaprevir and demonstrated that SCY-635 presented a lower risk of potential adverse drugdrug interactions when compared in vitro with other cyclophilin inhibitors.

About SCY-635 and SCYNEXIS’ Cyclophilin Inhibitor Platform
SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection. SCY-635 is the first candidate in a novel class of non-immunosuppressive, oral cyclophilin inhibitors owned by SCYNEXIS. Cyclophilins are a family of enzymatic proteins that assist in the folding and transport of other proteins synthesized within a cell. Scientists at SCYNEXIS have synthesized derivatives of Cyclosporine A in which cyclophilin binding activity (which mediates anti-HCV activity) is separated from calcineurin binding activity (which mediates immunosuppression). A growing body of scientific evidence indicates that non-immunosuppressive analogs of Cyclosporine A may have applications in multiple therapeutic areas. Cyclophilins play a central role in the pathophysiology of chronic viral infection, neuro- and cardiodegenerative diseases. Cyclophilin inhibition therefore represents an attractive target for drug discovery and development.

About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. Our record of success is demonstrated by the delivery of 11 pre-clinical and clinical drug candidates over the last 5 years. The Company, which is located in Research Triangle Park, North Carolina, is developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.

SCYNEXIS, Inc.
Terry Marquardt
Executive Director
Market Development & Communications
mailto:terry.marquardt@scynexis.com
Tel: +1 919‐544‐8603

SCYNEXIS Media Contacts:
Cory Tromblee
MacDougall Biomedical Communications
ctromblee@macbiocom.com
Tel. +1 781‐235‐3060

Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919‐878‐1144